Overview

Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer

Status:
Unknown status

Trial end date:
2021-08-01

Target enrollment:

Participant gender:

Summary

This is a randomized phase II trial comparing the first-line treatment with nab-paclitaxel plus S-1(AS) and nab-paclitaxel plus gemcitabine(AG) in advanced pancreatic ductal adenocarcinoma (PDA) with primary tumor nonexcision in Chinese patients.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel